Gyre Therapeutics, Inc. Cost of Revenue
Gyre Therapeutics, Inc. (GYRE) reported Cost of Revenue of $2.21 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-07
- Gyre Therapeutics, Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $2.21M, a 91.92% increase year-over-year.
- Gyre Therapeutics, Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $1.23M, a 37.25% increase year-over-year.
- Gyre Therapeutics, Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $1.74M, a 48.09% increase year-over-year.
- Gyre Therapeutics, Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $1.63M, a 69.94% increase year-over-year.
- Gyre Therapeutics, Inc. cost of goods and services sold for fiscal 2025 was $5.42M, a 39.44% increase from fiscal 2024.
- Gyre Therapeutics, Inc. cost of goods and services sold for fiscal 2024 was $3.88M, a 16.22% decline from fiscal 2023.
- Gyre Therapeutics, Inc. cost of goods and services sold for fiscal 2023 was $4.64M, a 3.28% decline from fiscal 2022.
- Gyre Therapeutics, Inc. cost of goods and services sold for fiscal 2022 was $4.79M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.21M 10-Q · filed 2026-08-07 | $3.44M 10-Q · filed 2026-08-07 | $5.18M derived: sum of 3 quarters · filed 2026-08-07 | $6.81M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $1.23M 10-Q · filed 2026-05-08 | $2.97M derived: sum of 2 quarters · filed 2026-05-08 | $4.60M derived: sum of 3 quarters · filed 2026-05-08 | $5.75M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $3.37M derived: sum of 2 quarters · filed 2026-03-13 | $4.52M derived: sum of 3 quarters · filed 2026-08-07 | $5.42M 10-K · filed 2026-03-13 |
| 2025-09-30 | $1.63M 10-Q · filed 2025-11-07 | $2.78M derived: sum of 2 quarters · filed 2026-08-07 | $3.67M 10-Q · filed 2025-11-07 | $4.85M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $1.15M 10-Q · filed 2026-08-07 | $2.04M 10-Q · filed 2026-08-07 | $3.22M derived: sum of 3 quarters · filed 2026-08-07 | $4.18M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $894.00K 10-Q · filed 2026-05-08 | $2.07M derived: sum of 2 quarters · filed 2026-05-08 | $3.03M derived: sum of 3 quarters · filed 2026-05-08 | $3.80M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $2.13M derived: sum of 2 quarters · filed 2026-03-13 | $2.90M derived: sum of 3 quarters · filed 2026-03-13 | $3.88M 10-K · filed 2026-03-13 |
| 2024-09-30 | $958.00K 10-Q · filed 2025-11-07 | $1.73M derived: sum of 2 quarters · filed 2025-11-07 | $2.71M 10-Q · filed 2025-11-07 | $3.96M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $770.00K 10-Q · filed 2025-08-11 | $1.75M 10-Q · filed 2025-08-11 | $3.00M derived: sum of 3 quarters · filed 2025-08-11 | $4.18M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $979.00K 10-Q · filed 2025-05-09 | $2.23M derived: sum of 2 quarters · filed 2025-05-09 | $3.41M derived: sum of 3 quarters · filed 2025-05-09 | $4.49M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $2.43M derived: sum of 2 quarters · filed 2025-03-17 | $3.51M derived: sum of 3 quarters · filed 2025-03-17 | $4.64M 10-K · filed 2025-03-17 |
| 2023-09-30 | $1.18M 10-Q · filed 2024-11-13 | $2.26M derived: sum of 2 quarters · filed 2024-11-13 | $3.39M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $1.08M 10-Q · filed 2024-08-13 | $2.20M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $1.13M 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $4.79M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |